Experimental combo aims to outsmart tough leukemia
NCT ID NCT05627232
First seen Nov 03, 2025 · Last updated Jun 22, 2026 · Updated 35 times
Summary
This early-phase trial tests two different drug combinations for people whose acute myeloid leukemia (AML) has returned or not responded to prior treatment. In Part 1, participants receive tazemetostat plus a standard chemotherapy called CPX-351. In Part 2, they get palbociclib before CPX-351. The study enrolls 24 adults and focuses on finding safe doses and watching for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Thomas Jefferson University Hospital
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tazemetostat and CPX-351 (liposomal daunorubicin-cytarabine) in Part 1; palbociclib followed by CPX-351 in Part 2
What this could lead to
If successful, this could point toward a new combination treatment for acute myeloid leukemia that has come back or not responded to standard therapy.
What could go wrong
This is a very early (Phase 1) trial with only 24 participants, so the main goal is safety, not proof of effectiveness. The combinations may cause serious side effects or fail to improve outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.